A Phase 3 interventional study of Calcipotriol plus betamethasone and Betamethasone-17,21-dipropionate in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 17 in phase 3, and was the 18th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,152 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 4th largest by enrollment of the 71 interventional ones that give a count, is one of 9 that started in 2010, is one of 20 in phase 3, and was the 25th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
Drug: Calcipotriol plus betamethasone
Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
Drug: Betamethasone-17,21-dipropionate
Calcipotriol 50 mcg/g in the topical suspension vehicle
Drug: Calcipotriene
The topical suspension vehicle alone
Drug: Topical suspension vehicle
Drug pages: Calcipotriene · Betamethasone
Topical suspension once daily for up to 8 weeks.
Topical suspension once daily for up to 8 weeks.
Topical suspension once daily for up to 8 weeks.
Topical suspension once daily for up to 8 weeks.
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4
The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.
Time frame: 4 weeks
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8
The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.
Time frame: week 8
Mean Percentage Change in PASI From Baseline to Week 4
At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.
Time frame: Baseline and 4 weeks
Mean Percentage Change in PASI From Baseline to Week 8
At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.
Time frame: Baseline and 8 weeks
The first subject's first visit was on 27-SEP-2010 and the last subject's last visit was on 29-MAR-2011. Hence the study had a duration of 26 weeks.
| Milestone | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Started | 482 | 479 | 96 | 95 |
| Completed | 444 | 417 | 82 | 77 |
| Not completed | 38 | 62 | 14 | 18 |
The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.
| participants | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4 | 64 | 60 | 5 | 2 |
The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.
| participants | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8 | 140 | 103 | 14 | 6 |
At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.
| percentage of change in PASI | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Mean Percentage Change in PASI From Baseline to Week 4 | -46.4 ± 30.2 | -42.7 ± 29.4 | -32.2 ± 27.3 | -17.4 ± 36.8 |
At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.
| percentage of change in PASI | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Mean Percentage Change in PASI From Baseline to Week 8 | -55.8 ± 34.4 | -48.6 ± 35.8 | -43.6 ± 34.1 | -20.9 ± 49.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LEO 80185 | — | 1/482 (0.2%) | 14/482 (2.9%) |
| Betamethasone | — | 7/479 (1.5%) | 15/479 (3.1%) |
| Calcipotriol | — | 0/96 (0%) | 5/96 (5.2%) |
| Topical Suspension Vehicle | — | 1/95 (1.1%) | 3/95 (3.2%) |
| Event | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| Suicide attemptPsychiatric disorders | 0/482 | 0/479 | 0/96 | 1/95 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/482 | 1/479 | 0/96 | 0/95 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/482 | 1/479 | 0/96 | 0/95 |
| CellulitisInfections and infestations | 0/482 | 1/479 | 0/96 | 0/95 |
| Cholecystitis acuteHepatobiliary disorders | 0/482 | 1/479 | 0/96 | 0/95 |
| HaematuriaRenal and urinary disorders | 0/482 | 1/479 | 0/96 | 0/95 |
| NephrolithiasisRenal and urinary disorders | 0/482 | 1/479 | 0/96 | 0/95 |
| Stent placementSurgical and medical procedures | 0/482 | 1/479 | 0/96 | 0/95 |
| Suicidal ideationPsychiatric disorders | 0/482 | 1/479 | 0/96 | 0/95 |
| HypertensionVascular disorders | 1/482 | 0/479 | 0/96 | 0/95 |
| Event | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/482 | 15/479 | 5/96 | 3/95 |
| Age, Continuous(years) | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 48.7 ± 13.4 | 48.5 ± 13.8 | 48 ± 13.7 | 49.4 ± 13.0 | 48.6 ± 13.5 |
| Sex: Female, Male(Participants) | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle | Total |
|---|---|---|---|---|---|
| Female | 198 | 193 | 36 | 35 | 462 |
| Male | 284 | 286 | 60 | 60 | 690 |
| Region of Enrollment(participants) | LEO 80185 | Betamethasone | Calcipotriol | Topical Suspension Vehicle | Total |
|---|---|---|---|---|---|
| United States | 482 | 479 | 96 | 95 | 1152 |
Plan to share: No
The record gives a start of Sep 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 2 years 1 month after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone